GlassScriptPhysician profile
Sylvia Tony
NPI 1063989770
$3,568.46
in general payments reported to CMS, 2019-2025
43 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.13 · 2022: $81.35 · 2023: $797 · 2024: $1,488 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,472.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $533.67 | 2023-2025 | |
| Ucb, INC. | $347.82 | 2023-2025 | Briviact, Nayzilam, Fintepla |
| Novartis Pharmaceuticals Corporation | $222.92 | 2023-2025 | |
| Biogen, INC. | $192.32 | 2024-2025 | Tysabri, Vumerity, Skyclarys |
| Emd Serono, INC. | $182.23 | 2022-2025 | Mavenclad |
| Tg Therapeutics, INC. | $173.48 | 2023-2025 | |
| Amgen INC. | $149.26 | 2024-2025 | Uplizna, Aimovig |
| Takeda Pharmaceuticals U.S.A., INC. | $129.12 | 2024-2025 | Hyqvia |
| Alnylam Pharmaceuticals INC. | $126.00 | 2023-2025 | Amvuttra |
| Csl Behring | $124.81 | 2023-2025 | Hizentra |
| Pfizer INC. | $103.44 | 2024-2025 | |
| Genentech USA, INC. | $100.94 | 2024-2025 | Enspryng, Evrysdi, Ocrevus |
| Alexion Pharmaceuticals, INC. | $96.94 | 2023-2025 | Ultomiris |
| Genzyme Corporation | $87.67 | 2025 | |
| Jazz Pharmaceuticals INC. | $84.53 | 2023-2024 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $80.73 | 2021-2023 | Ponvory |
| Neurocrine Biosciences, INC. | $73.72 | 2024-2025 | Ingrezza |
| Ge Healthcare | $57.06 | 2023-2025 | |
| Sk Life Science, INC. | $50.94 | 2023-2024 | |
| Lundbeck LLC | $49.10 | 2023-2025 | Vyepti |
| Sumitomo Pharma America, INC. | $47.94 | 2023-2024 | Aptiom |
| Immedica Pharma US, INC. | $45.66 | 2024 | |
| Argenx US, INC. | $39.39 | 2023-2025 | Vyvgart |
| Eisai INC. | $35.95 | 2023-2024 | |
| Lilly USA, LLC | $30.18 | 2023-2024 | Emgality, Reyvow |
| Cycle Pharmaceuticals INC | $29.25 | 2025 | Tascenso Odt, Bafiertam |
| Neurelis, INC. | $27.45 | 2024 | Valtoco |
| Hospira, INC. | $27.36 | 2023 | |
| Merz Pharmaceuticals, LLC | $26.47 | 2024 | Inbrija, Ampyra |
| Ani Pharmaceuticals, INC. | $26.12 | 2023 | Purified Cortrophin Gel |
| Acadia Pharmaceuticals INC | $24.38 | 2025 | Daybue |
| Impel Pharmaceuticals LLC | $24.14 | 2025 | Trudhesa |
| Banner Life Sciences, LLC | $22.01 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $21.99 | 2024 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $21.93 | 2024 | Dojolvi |
| Biohaven Pharmaceutical Holding Company LTD. | $20.91 | 2022 | |
| Upsher-Smith Laboratories LLC | $20.03 | 2023 | |
| Octapharma USA, INC. | $19.56 | 2023 | Panzyga |
| Medtronic, INC. | $19.18 | 2025 | Synchromedii |
| Astrazeneca Pharmaceuticals LP | $18.87 | 2024 | Wainua |
| Averitas Pharma INC. | $18.78 | 2025 | Qutenza |
| Livanova USA, INC. | $18.28 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Tanabe Pharma America, INC. | $15.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Tony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.